Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (13949)	2/5/2005 10:07:53 AM
From: gg cox	Respond to of 14101

THE TICKER CELEBREX: FDA seeks advice on safety warning Bloomberg News Published February 5, 2005 WASHINGTON -- The Food and Drug Administration asked a panel of advisers to consider what safety information is needed to allow continued sales of Pfizer Inc.'s Celebrex painkiller and the introduction of similar drugs in the U.S. The FDA posted on its Web site Friday reports intended to prepare doctors and researchers for a Feb. 16-18 meeting on painkiller safety. The agency called the meeting after a Merck & Co. study linked its Vioxx painkiller to risk of heart attacks and strokes, leading to the biggest drug withdrawal ever. The FDA staff asked advisers to the agency to consider whether drugs similar to Vioxx--including Celebrex, Merck's Arcoxia and Novartis AG's Prexige--may pose the same risk. The medicines were designed to target the Cox-2 enzyme, linked to pain. Among reports the FDA posted on its Web site was one saying that Arcoxia may have a "safety signal" for cardiovascular risk while offering "limited" benefit for the stomach. Another report said a study of Novartis's Prexige "had not definitively answered the question" of whether it poses more of a heart risk than older painkillers. chicagotribune.com